Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Leukemia

Free Subscription 04.03.2019 1 Acta Haematol 1 Ann Hematol 1 Ann Oncol 1 Biochem Pharmacol 4 Blood 1 Bone Marrow Transplant 4 Cancer 1 Cancer Chemother Pharmacol 1 Eur J Haematol 3 Exp Hematol 2 Hematol Oncol Clin North Am 4 J Pediatr Hematol Oncol 1 Leuk Lymphoma 1 Leuk Res 1 Leukemia 4 Oncogene

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Acta Haematol

1. LI Z, Liu Y, Wang Q, Chen L, et al
   Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis.
   Acta Haematol. 2019;141:164-175.
   PubMed     Text format     Abstract available
   
   

   
   Ann Hematol

2. DULUCQ S, Etienne G, Morisset S, Klein E, et al
   Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
   Ann Hematol. 2019 Feb 23. pii: 10.1007/s00277-019-03633.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

3. RUPPERT AS, Yin J, Davidian M, Tsiatis AA, et al
   Application of a Sequential Multiple Assignment Randomized Trial (SMART) Design in Older Patients with Chronic Lymphocytic Leukemia.
   Ann Oncol. 2019 Feb 25. pii: 5364262. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Biochem Pharmacol

4. LIAO HC, Chou YJ, Lin CC, Liu SH, et al
   Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
   Biochem Pharmacol. 2019 Feb 26. pii: S0006-2952(19)30066.
   PubMed     Text format     Abstract available
   
   

   
   Blood

5. MORANDE PE, Sivina M, Uriepero A, Seija N, et al
   Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
   Blood. 2019 Feb 27. pii: blood-2018-09-876292. doi: 10.1182/blood-2018-09-876292
   PubMed     Text format     Abstract available
   
   
6. SANZ MA, Fenaux P, Tallman MS, Estey EH, et al
   Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
   Blood. 2019 Feb 25. pii: blood-2019-01-894980. doi: 10.1182/blood-2019-01-894980
   PubMed     Text format     Abstract available
   
   
7. KAUFMANN KB, Garcia-Prat L, Liu Q, Ng SWK, et al
   A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency.
   Blood. 2019 Feb 22. pii: blood-2018-10-881441. doi: 10.1182/blood-2018-10-881441
   PubMed     Text format     Abstract available
   
   
8. SANCHEZ-MARTINEZ D, Baroni ML, Gutierrez-Aguera F, Roca-Ho H, et al
   Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
   Blood. 2019 Feb 22. pii: blood-2018-10-882944. doi: 10.1182/blood-2018-10-882944
   PubMed     Text format     Abstract available
   
   

   
   Bone Marrow Transplant

9. GODWIN CD, Fromm JR, Othus M, Sandmaier BM, et al
   Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission.
   Bone Marrow Transplant. 2019 Feb 25. pii: 10.1038/s41409-019-0481.
   PubMed     Text format    
   
   

   
   Cancer

10. BENTON CB, Boddu PC, DiNardo CD, Bose P, et al
    Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.31986.
    PubMed     Text format     Abstract available
    
    
11. GHAZAWI FM, Le M, Cyr J, Netchiporouk E, et al
    Analysis of acute myeloid leukemia incidence and geographic distribution in Canada from 1992 to 2010 reveals disease clusters in Sarnia and other industrial US border cities in Ontario.
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.32034.
    PubMed     Text format     Abstract available
    
    
12. SAMET JM, Cockburn M
    What can be learned from mapping the occurrence of acute myeloid leukemia?
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.32031.
    PubMed     Text format    
    
    
13. SHARMA S, Rai KR
    Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options.
    Cancer. 2019 Feb 26. doi: 10.1002/cncr.31931.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

14. NAUSHAD SM, Dorababu P, Rupasree Y, Pavani A, et al
    Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2019 Feb 26. pii: 10.1007/s00280-019-03803.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Haematol

15. CAPODANNO I, Tamagnini E, Alfieri P, Codeluppi K, et al
    Home Care of Acute Leukemia Patients: from Active Therapy to End-of-Life and Palliative Care. The Three-year Experience of a Single Centre.
    Eur J Haematol. 2019 Feb 22. doi: 10.1111/ejh.13224.
    PubMed     Text format     Abstract available
    
    

    
    Exp Hematol

16. VALDEZ BC, Tang X, Li Y, Murray D, et al
    Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.
    Exp Hematol. 2018;67:49-59.
    PubMed     Text format     Abstract available
    
    
17. BARVE A, Casson L, Krem M, Wunderlich M, et al
    Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.
    Exp Hematol. 2018;67:18-31.
    PubMed     Text format     Abstract available
    
    
18. HERNANDEZ-SANCHEZ M, Rodriguez-Vicente AE, Gonzalez-Gascon Y Marin I, Quijada-Alamo M, et al
    DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia patients and chromosomal gains.
    Exp Hematol. 2019 Feb 23. pii: S0301-472X(19)30073.
    PubMed     Text format     Abstract available
    
    

    
    Hematol Oncol Clin North Am

19. MCREYNOLDS LJ, Calvo KR, Holland SM
    Germline GATA2 Mutation and Bone Marrow Failure.
    Hematol Oncol Clin North Am. 2018;32:713-728.
    PubMed     Text format     Abstract available
    
    
20. SIEFF CA
    Introduction to Acquired and Inherited Bone Marrow Failure.
    Hematol Oncol Clin North Am. 2018;32:569-580.
    PubMed     Text format     Abstract available
    
    

    
    J Pediatr Hematol Oncol

21. SANO H, Mochizuki K, Kobayashi S, Ono S, et al
    Two Occurrences of Leukemia Relapse Due to Mismatched HLA Loss After Haploidentical Stem Cell Transplantation From Different Family Donors With KIR Ligand Mismatch.
    J Pediatr Hematol Oncol. 2019 Feb 21. doi: 10.1097/MPH.0000000000001443.
    PubMed     Text format     Abstract available
    
    
22. PAUL MR, Wong V, Aristizabal P, Kuo DJ, et al
    Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
    J Pediatr Hematol Oncol. 2019 Feb 22. doi: 10.1097/MPH.0000000000001440.
    PubMed     Text format     Abstract available
    
    
23. TSUMURA Y, Yamada Y, Osumi T, Kato M, et al
    Successful Treatment With ATRA and Arsenic Trioxide for a Child With Down Syndrome and Acute Promyelocytic Leukemia.
    J Pediatr Hematol Oncol. 2019 Feb 22. doi: 10.1097/MPH.0000000000001438.
    PubMed     Text format     Abstract available
    
    
24. CORTELLAZZO WIEL L, Pastore S, Taddio A, Tommasini A, et al
    A Case of Uveitis in a Patient With Juvenile Myelomonocytic Leukemia Successfully Treated With Adalimumab.
    J Pediatr Hematol Oncol. 2019 Feb 22. doi: 10.1097/MPH.0000000000001448.
    PubMed     Text format     Abstract available
    
    

    
    Leuk Lymphoma

25. SALEHI S, Astle JM, Sadigh S, Lake J, et al
    Myeloid neoplasm with eosinophilia and PCM1-JAK2 associated with acute promyelocytic leukemia with PML-RARA.
    Leuk Lymphoma. 2019 Feb 26:1-5. doi: 10.1080/10428194.2019.1581927.
    PubMed     Text format    
    
    

    
    Leuk Res

26. SPACEK M, Obrtlikova P, Hrobkova S, Cmunt E, et al
    Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab.
    Leuk Res. 2019;79:17-21.
    PubMed     Text format     Abstract available
    
    

    
    Leukemia

27. STEINHERZ PG, Seibel NL, Sather H, Ji L, et al
    Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.
    Leukemia. 2019 Feb 28. pii: 10.1038/s41375-019-0422.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

28. LAU BW, Huh K, Madero-Marroquin R, De Marchi F, et al
    Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity.
    Oncogene. 2019;38:687-698.
    PubMed     Text format     Abstract available
    
    
29. CHEN-WICHMANN L, Shvartsman M, Preiss C, Hockings C, et al
    Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
    Oncogene. 2019;38:261-272.
    PubMed     Text format     Abstract available
    
    
30. STAMM H, Klingler F, Grossjohann EM, Muschhammer J, et al
    Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
    Oncogene. 2018;37:5269-5280.
    PubMed     Text format     Abstract available
    
    
31. GERLACH D, Tontsch-Grunt U, Baum A, Popow J, et al
    The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
    Oncogene. 2018;37:2687-2701.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: